EGFR and hepatocellular carcinoma: Considering that apatinib influences sorafenib-resistant HCC by inhibiting the EGFR/JNK/ERK signaling pathway, it is plausible to speculate that apatinib could inhibit the development of sorafenib-resistant HCC through the EMT process and EGFR/JNK/ERK pathway.